Abstract: The present invention relates to an ophthalmic composition for promoting tear secretion, the composition comprising 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile or a salt thereof.

Abstract: The inventive ophthalmic composition comprises: (A) polyvinyl pyrrolidone K90; and (B) at least one selected from the group consisting of an oil component, a grease component and polyethylene glycol. The ophthalmic composition alleviates a sticky sensation to ensure an excellent use sensation.

Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

Abstract: The inventive ophthalmic composition comprises: (A) polyvinyl pyrrolidone K90; and (B) at least one selected from the group consisting of an oil component, a grease component and polyethylene glycol. The ophthalmic composition alleviates a sticky sensation to ensure an excellent use sensation.

Abstract: An engineering method for establishing an engineering system includes establishing the engineering system in a virtual system by performing a communication and permitting an access to the virtual system via an internet, the communication being performed by using a service which is provided via the internet, the service being used by a first communication system which is connected to the internet, the virtual system being disposed in the first communication system, and the virtual system virtually implementing the engineering system, and inspecting the engineering system by performing an access to an inspection system via a virtual private network, the access is performed by a second communication system which is connected to the virtual private network, the inspection system being disposed in the second communication system, and the inspection system inspecting operations of the engineering system which is established in the virtual system.

Abstract: An video receiving apparatus which reduces waiting time till image is displayed on a monitor include: a plurality of authentication executing units which perform respectively an authentication process to the external devices connected to each of the plurality of input terminals; a terminal selecting unit which selects one of the plurality of input terminals as a video input terminal based on an operation input from outside; an video receiving unit which receives the video information through one of the authentication executing units corresponding to the selected input terminal from the external devices connected through the selected input terminal; and a display control unit which outputs the received video information to a monitor.

Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.

Abstract: An ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent has an advantage that the loss of the geranylgeranylacetone content during long-term storage is very little. This is because of reduced adsorption of geranylgeranylacetone to a wall of an ophthalmic container. The ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent also has an advantage that adsorption of geranylgeranylacetone to a contact lens is little. Further, the ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent hardly becomes white turbid even when stored at low temperature.

Abstract: An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little.

Abstract: An video receiving apparatus which reduces waiting time till image is displayed on a monitor include: a plurality of authentication executing units which perform respectively an authentication process to the external devices connected to each of the plurality of input terminals; a terminal selecting unit which selects one of the plurality of input terminals as a video input terminal based on an operation input from outside; an video receiving unit which receives the video information through one of the authentication executing units corresponding to the selected input terminal from the external devices connected through the selected input terminal; and a display control unit which outputs the received video information to a monitor.

Abstract: An video receiving apparatus which reduces waiting time till image is displayed on a monitor include: a plurality of authentication executing units which perform respectively an authentication process to the external devices connected to each of the plurality of input terminals; a terminal selecting unit which selects one of the plurality of input terminals as a video input terminal based on an operation input from outside; an video receiving unit which receives the video information through one of the authentication executing units corresponding to the selected input terminal from the external devices connected through the selected input terminal; and a display control unit which outputs the received video information to a monitor.

Abstract: An engineering method for establishing an engineering system includes establishing the engineering system in a virtual system by performing a communication and permitting an access to the virtual system via an internet, the communication being performed by using a service which is provided via the internet, the service being used by a first communication system which is connected to the internet, the virtual system being disposed in the first communication system, and the virtual system virtually implementing the engineering system, and inspecting the engineering system by performing an access to an inspection system via a virtual private network, the access is performed by a second communication system which is connected to the virtual private network, the inspection system being disposed in the second communication system, and the inspection system inspecting operations of the engineering system which is established in the virtual system.

Abstract: An ophthalmic composition comprising geranylgeranylacetone and a fat-soluble antioxidant has an advantage that adsorption of geranylgeranylacetone to a wall of a container is remarkably reduced and thereby the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the composition is remarkably reduced. Adsorption of the fat-soluble antioxidant to a wall of a container is also reduced due to combination with geranylgeranylacetone.

Abstract: An ophthalmic composition comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone protects various types of retinal cells from degeneration, impairment or destruction, thereby remarkably promoting the survival. Consequently, the composition exhibits a remarkable effect of preventing, ameliorating or treating various retinal diseases. In addition, the composition hardly becomes white turbid during storage.

Abstract: The present invention provides an ophthalmic aqueous composition having an oil-in-water emulsion including a vegetable oil, a non-ionic surfactant, and a terpenoid, wherein an average particle diameter of emulsion particles is within the range of 30 nm to 300 nm.

Abstract: An electronic text viewing apparatus includes a viewing application unit that outputs viewing data for displaying a text in a viewable manner, a display unit that displays the viewing data and a fast reading button for receiving a fast reading request for the viewing data, a viewing data requesting unit that issues a request for acquirement of the viewing data to the viewing application unit, and acquires the viewing data to be viewed, a setting data storage unit that stores setting data for the acquired viewing data, and a fast reading viewer control unit that, when the fast reading button is pressed, converts the viewing data into fast reading viewer data by performing display format conversion, display speed control and scroll control of the viewing data, and displays the fast reading viewer data and a return button for converting the fast reading viewer data to the viewing data.

Abstract: Application of a pharmaceutical preparation comprising geranylgeranylacetone to the mucosa of, for example, the eye, nose, oral cavity or pharynx can efficiently prevent, ameliorate or treat retinal diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy.

Abstract: An video receiving apparatus which reduces waiting time till image is displayed on a monitor include: a plurality of authentication executing units which perform respectively an authentication process to the external devices connected to each of the plurality of input terminals; a terminal selecting unit which selects one of the plurality of input terminals as a video input terminal based on an operation input from outside; an video receiving unit which receives the video information through one of the authentication executing units corresponding to the selected input terminal from the external devices connected through the selected input terminal; and a display control unit which outputs the received video information to a monitor.

Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.